– USA, FL – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Prime carotid stent system for the prevention of stroke, announced the appointment of Ray Cohen to its Board of Directors.
About Raymond W. Cohen
Ray Cohen has over 40 years of leadership experience in medical technology with a successful track record of scaling commercial operations and creating shareholder value through market leadership and successful exit transactions. He was the CEO and co-founder of Axonics, Inc., which he took public in late 2018 and led through its $3.7 billion acquisition by Boston Scientific in November 2024. Axonics earned recognition as the number one fastest-growing company in the Americas by Deloitte and the Financial Times in 2021.
Until May of 2025, Ray Cohen served as Chairman of SoniVie Ltd., a clinical-stage company focused on a device treatment for hypertension, until it was acquired by Boston Scientific for $600 million.
Ray Cohen serves as an independent director for Kestra Medical (Nasdaq: KMTS) and PE-backed Spectrum Vascular Inc., as well as Chairman of privately held Nalu Medical and Vice Chairman of privately held Tulavi, Inc.
Previously, Ray Cohen was CEO of Vessix Vascular, Inc., and publicly traded Cardiac Science Inc., a pioneer in automated external defibrillators, which was later acquired by Zoll Medical. His work has earned him numerous honors, including the MedTech MVP Award, EY Entrepreneur of the Year, and a Lifetime Achievement Award from SoCalBio.
“The CGuard Prime stent system represents a true best-in-class innovation. Moreover, the Company’s singular focus, entrepreneurial agility, and deep clinical commitment uniquely position it to penetrate and lead the U.S. carotid stent market,” said Mr. Cohen. “I’m looking forward to sharing my experiences scaling high-growth MedTech businesses to support Marvin and his team as they strive to execute with precision, capture market share, and deliver sustained long-term value.”
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on our website.
For more: https://www.inspiremd.com/en/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.